Clinically meaningful efficacy outcomes observed at one year maintained to two years of treatment

Referral lower for patients with mental health admissions or mental health diagnoses and with increasing age

Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients

Inferior overall survival seen in Latine adults compared with Black patients in a multivariable analysis

Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation

Additionally, vasomotor symptoms remain undertreated

Metabolic risk factors contribute to new-onset diabetes mellitus among those treated with pitavastatin or placebo

Most of the potential prevented deaths would occur in low- and middle-income countries

Cumulative incidence of full cognitive recovery higher with postoperative SRS versus WBRT and for SRS alone versus SR + WBRT

No differences seen for quality of life and tumor control with localized prostate cancer